Supernus Pharmaceuticals Stock Forum

🗓️ Last week’s PDUFAs:
$Supernus Pharmaceuticals(SUPN.US)$ : CRL 4/8/24 🙁
⇒ SPN-830
⇒ OFF episodes in PD
⇒ NDA
⇒ PDUFA: 4/5/24
$Legend Biotech(LEGN.US)$ & $Johnson & Johnson(JNJ.US)$ : Approved 🎉
⇒ CARVYKTI (cilta-cel)
⇒ Multiple myeloma
⇒ sBLA
⇒ PDUFA: 4/5/24
$AstraZeneca(AZN.US)$ : Approved 🎉
⇒ Enhertu
⇒ HER2+ solid tumors
⇒ sBLA
⇒ PDUFA: Q2 2024
$2seventy bio(TSVT.US)$ & $Bristol-Myers Squibb(BMY.US)$ : Approved 🎉
⇒ Abecma
⇒ Multiple myeloma
⇒ sBLA
⇒ Delayed PDUFA
$Vanda Pharmaceuticals(VNDA.US)$...

$Supernus Pharmaceuticals(SUPN.US)$ so many insider selling non stop. hmmm

$Supernus Pharmaceuticals(SUPN.US)$
waiting patiently for fda 😌🙏

🗓️ Last week’s PDUFAs:
$Akebia Therapeutics(AKBA.US)$ : Approved 🎉
⇒ Vafseo (Vadadustat)
⇒ Anemia due to CKD
⇒ NDA
⇒ PDUFA: 3/27/24
$Merck & Co(MRK.US)$ : Approved 🎉
⇒ WINREVAIR (sotatercept)
⇒ Pulmonary arterial hypertension
⇒ BLA
⇒ PDUFA: 3/26/24
$AstraZeneca(AZN.US)$ : Approved 🎉
⇒ Ultomiris (ravulizumab)
⇒ NMOSD
⇒ sBLA
$Regeneron Pharmaceuticals(REGN.US)$ : CRL 🙁
⇒ Odronextamab
⇒ r/r FL and r/r DLBCL
⇒ BLA
⇒ PDUFA: 3/31/24
📌 This week’s PDUFAs: 🚨
$AstraZeneca(AZN.US)$ : 🤔
⇒...

The FDA PDUFA Calendar is a chronological calendar of PDUFA target dates as well as Advisory meetings (ADCOMM). PDUFA target dates are dates by which the FDA aims to deliver their decision regarding an NDA or BLA filing. These decisions can however come before the PDUFA target date.
$Vanda Pharmaceuticals(VNDA.US)$$Legend Biotech(LEGN.US)$$Supernus Pharmaceuticals(SUPN.US)$$ImmunityBio(IBRX.US)$$Aquestive Therapeutics(AQST.US)$$X4 Pharmaceuticals(XFOR.US)$$Liquidia(LQDA.US)$$Neurocrine Biosciences(NBIX.US)$$Moderna(MRNA.US)$$Day One Biopharmaceuticals(DAWN.US)$
...

$Supernus Pharmaceuticals(SUPN.US)$ 👀

Gainers：
• $Innoviz Technologies(INVZ.US)$ +18.7% (selected by "large automotive group manufacturer" to become its direct LiDAR supplier across multiple brands)
• $Hilltop Holdings(HTH.US)$ +15.7% (commenced a modified "Dutch auction" tender offer to purchase for cash up to $400 mln of its common stock at a price per share not less than $28,00 and not greater than $32.00 less any applicable withholding taxes and without interest usin...

$Supernus Pharmaceuticals(SUPN.US)$
Supernus Pharmaceuticals agreed to acquire Adamas Pharmaceuticals for $8.10 a share in cash, or about $400 million, for two drugs approved for use in patients with Parkinson's disease. The transaction also includes two contingent value rights (CVR) with a total value of $1 per share in cash, or approximately $50 million. The initial cash consideration represents a premium of about 75% to Adamas' Oct. 8 closing share price.